Receive The Newest Study Notifications

  At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First time the benefit of two doses of a fixed...

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead candidate abexinostat, an orally dosed, hydroxamic...

Surmodics has completed enrolment in TRANSCEND, its pivotal clinical trial for the SurVeil drug-coated balloon (DCB). “TRANSCEND is a rigorous level one, randomised controlled trial that comes at a very important time for the vascular and interventional community,”...

  “The enrollment of the first patient in the United States is in line with our wish to make our product internationally available to patients suffering from dRTA” Tweet this Advicenne (Euronext Paris & Brussels: ADVIC - FR0013296746) (Paris:ADVIC)...

VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs). VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and...

 OPKO Health, Inc. (NASDAQ: OPK) today announced that the last patient has completed the final visit in the Company’s pivotal Phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH-CTP) for treatment of growth hormone deficiency in...

  PHILADELPHIA, August 27, 2019 - Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia developing novel compounds to treat neurodegenerative diseases, announces the publication of its Phase 2a RASMET study. The article entitled...

- SurModics, Inc.(NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB)....

- QIDP and FDA-Fast-Track-Designated first of a new class of antibiotics - First evidence of human safety in multiple ascending doses and favorable PK profile - Fecal concentrations exceeded those known to inhibit C. difficile several hundred-fold - Significantly less...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of the Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatment, compared to oral immediate-release...

South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1 clinical trial will be conducted among 90 patients who suffer...

United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,557,874 October 15, 2013), for the healthcare and wound care sectors, today...

Cancer and neurological condition focused Evgen Pharma said the last study visit had been conducted for the final patient entered into a recent clinical trial of a treatment for subarachnoid haemorrhage, a type of stroke. In the placebo-controlled SAS phase II...

Boasting over one billion monthly active users, as well as more than 50 billion photos shared, Instagram is one of the most engaging social media platforms. Not only is it a popular platform among young adults aged 18-24, but businesses have taken advantage of its...

- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that its current cash position, which includes the $6.7 million in net...

New draft guidance features recommendations on the development and labeling of cancer drugs for men with breast cancer August 26, 2019 — The U.S. Food and Drug Administration (FDA) released a new draft guidance that encourages including male patients in breast...

Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the last patient has been enrolled in the...

Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound.  ONC206 is the first of the family of drug candidates,...

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. District Court of Delaware has set a trial date for Lipocine's patent infringement lawsuit against Clarus's...

- Trial leads to discovery that onvansertib stops rise in PSA in patients with treatment-resistant, highly-aggressive and difficult-to-treat androgen-receptor variant 7 (AR-V7) tumors - Data demonstrates efficacy of onvansertib in patients showing early signs of...